近5年来我国眼底病的诊疗水平快速提高,国际上新的诊疗理念、诊疗方法、诊疗设备不断被引入国内,极大地促进了国内眼底病诊疗技术的发展.在诊断方面,频域相干光断层扫描和眼底自发荧光检测技术的应用,不仅为临床诊断提供了更为详尽的图像信息,还有助于更加全面而深入地了解眼底疾病的特征及病理机制,引领我们进入了一个眼底疾病观察的新时代.在治疗方面,我国学者更是积极开展具有创新意义的临床研究,例如组织国内黄斑裂孔视网膜脱离治疗模式的多中心研究,开发具有自主知识产权的全人源抗体类融合蛋白KH902,采用带Bruch膜自体片状视网膜色素上皮移植并治疗年龄相关性黄斑变性、光动力疗法治疗中心性浆液性脉络膜视网膜病变、20G小切口微创玻璃体手术和视网膜中央动脉栓塞手术治疗技术等,有相当数量的眼底病临床研究论文在科学引文索引(SCI)收录的杂志上发表.由此表明我国眼底病临床研究已逐步走向世界并进一步与国际接轨.%In the past 5 years, the diagnosis and management of ocular fundus diseases in China has been improved remarkably. Up-to-date international concepts of diagnosis and management, methods, and equipments have been introduced into China, which have promoted the therapeutic technology of ocular fundus diseases. In the field of diagnosis, the application of frequency-domain optical coherence tomography and fundus autofluorescence detection technology not only provided more detailed image information for clinical diagnosis, but also helped clinical ophthalmologists to understand the features and pathogenesis of ocular fundus diseases comprehensively, leading the doctors into a new era of examination of ocular fundus diseases. In the field of treatment, Chinese researchers actively performed innovative clinical studies, such as organizing domestic multi-center studies of various therapies of macular hole retinal detachment,developing full-length humanized antibody fusion protein KH902 with intellectual property rights, using implants of autologous retinal pigment epithelium patch with Bruch membrane to treat age-related macular degeneration, using photodynamic therapy to treat central serous chorioretinopathy, 20 gauge small incision vitrectomy and surgical therapy of central retinal artery occlusion, etc. Moreover, certain amounts of high quality clinical papers have been published in SCI journals, which showed that clinical research of ocular fundus diseases in China has entered the field of international ophthalmology and has geared to international standards.
展开▼
